Accès ouvert
2025
article
OpenAlex
Rudy Mevizou, Dana Naim, Florent Cauchois, Cécile Naudin et autres
The mechanistic target of rapamycin complex 2 (mTORC2) signaling pathway, which regulates cell growth and migration, exhibits oncogenic function in colorectal cancer (CRC). mTORC2 signaling is primarily activated by a complex assembly of mTOR, RICTOR, SIN1, and mLST8; however, the mechanisms by …
fr
(code pays fourni par la source)
2025
preprint
OpenAlex
Rudy Mevizou, Dana Naim, Florent Cauchois, Cécile Naudin et autres
ABSTRACT The mechanistic target of rapamycin complex 2 (mTORC2) signaling pathway, which regulates cell growth and migration, exhibits oncogenic function in colorectal cancer (CRC). mTORC2 signaling is primarily activated by a complex assembly of mTOR, RICTOR, SIN1, and mLST8, but how dysregulation …
fr
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Anil K. Mondru, Beth Wilkinson, Mohammad Abdullah Aljasir, Ahmed Alrumayh et autres
Malignant melanoma, an aggressive skin cancer with a poor prognosis, frequently features BRAFV600E mutation resulting in activation of the MAPK pathway and melanocyte proliferation and survival. BRAFV600E inhibitors like vemurafenib and dabrafenib have enhanced patient survival, yet drug resistance remains a significant …
gb
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Rachel Carter, Mateus Milani, Michael Bruce Butterworth, Ahoud Alotibi et autres
Abstract Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide, with overall survival of less than 50%. Current therapeutic strategies involving a combination of surgery, radiation, and/or chemotherapy are associated with debilitating side effects, highlighting …
gb
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Aoula Al-Zebeeby, Meike Vogler, Mateus Milani, Caitlin Richards et autres
BH3 mimetics are novel targeted drugs with remarkable specificity, potency and enormous potential to improve cancer therapy. However, acquired resistance is an emerging problem. We report the rapid development of resistance in chronic lymphocytic leukemia cells isolated from patients exposed to increasing …
gb, de
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Georgia Greaves, Mateus Milani, Michael Bruce Butterworth, Rachel Carter et autres
The impressive selectivity and efficacy of BH3 mimetics for treating cancer has largely been limited to BCL-2 dependent hematological malignancies. Most solid tumors depend on other anti-apoptotic proteins, including MCL-1, for survival. The recent description of S63845 as the first specific and …
gb, us
(code pays fourni par la source)
Accès ouvert
2018
conference-abstract
OpenAlex
Georgia Greaves, Mateus Milani, Dominic P. Byrne, R. Carter et autres
Introduction Abnormal cell survival through resistance to apoptosis is a cardinal feature of most malignancies and plays a key role in chemoresistance. As the major regulators of the intrinsic mitochondrial pathway of apoptosis, the pro-survival BCL-2 family proteins (BCL-2, BCL-XL and MCL-1) …
gb, us
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
Mateus Milani, Dominic P. Byrne, Georgia Greaves, Michael Bruce Butterworth et autres
Abstract The concept of using BH3 mimetics as anticancer agents has been substantiated by the efficacy of selective drugs, such as Navitoclax and Venetoclax, in treating BCL-2-dependent haematological malignancies. However, most solid tumours depend on MCL-1 for survival, which is highly amplified …
gb
(code pays fourni par la source)